265 related articles for article (PubMed ID: 20385495)
1. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
Phillips KA; Ribi K; Sun Z; Stephens A; Thompson A; Harvey V; Thürlimann B; Cardoso F; Pagani O; Coates AS; Goldhirsch A; Price KN; Gelber RD; Bernhard J
Breast; 2010 Oct; 19(5):388-95. PubMed ID: 20385495
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
3. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
Giobbie-Hurder A; Price KN; Gelber RD; ;
Clin Trials; 2009 Jun; 6(3):272-87. PubMed ID: 19528136
[TBL] [Abstract][Full Text] [Related]
4. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
Chirgwin J; Sun Z; Smith I; Price KN; Thürlimann B; Ejlertsen B; Bonnefoi H; Regan MM; Goldhirsch A; Coates AS;
Breast Cancer Res Treat; 2012 Jan; 131(1):295-306. PubMed ID: 21892704
[TBL] [Abstract][Full Text] [Related]
5. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
6. Update of the BIG 1-98 Trial: where do we stand?
Joerger M; Thürlimann B
Breast; 2009 Oct; 18 Suppl 3():S78-82. PubMed ID: 19914548
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
8. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
; Mouridsen H; Giobbie-Hurder A; Goldhirsch A; Thürlimann B; Paridaens R; Smith I; Mauriac L; Forbes J; Price KN; Regan MM; Gelber RD; Coates AS
N Engl J Med; 2009 Aug; 361(8):766-76. PubMed ID: 19692688
[TBL] [Abstract][Full Text] [Related]
9. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.
Moy B; Tu D; Pater JL; Ingle JN; Shepherd LE; Whelan TJ; Goss PE
Ann Oncol; 2006 Nov; 17(11):1637-43. PubMed ID: 16936184
[TBL] [Abstract][Full Text] [Related]
11. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.
Whelan TJ; Goss PE; Ingle JN; Pater JL; Tu D; Pritchard K; Liu S; Shepherd LE; Palmer M; Robert NJ; Martino S; Muss HB
J Clin Oncol; 2005 Oct; 23(28):6931-40. PubMed ID: 16157934
[TBL] [Abstract][Full Text] [Related]
12. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
13. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).
Wasan KM; Goss PE; Pritchard PH; Shepherd L; Palmer MJ; Liu S; Tu D; Ingle JN; Heath M; Deangelis D; Perez EA
Ann Oncol; 2005 May; 16(5):707-15. PubMed ID: 15817595
[TBL] [Abstract][Full Text] [Related]
14. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
15. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Forbes JF
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
[TBL] [Abstract][Full Text] [Related]
16. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
Koeberle D; Thuerlimann B
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):55-66. PubMed ID: 17912636
[TBL] [Abstract][Full Text] [Related]
17. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
18. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
[TBL] [Abstract][Full Text] [Related]
19. Letrozole in the neoadjuvant setting: the P024 trial.
Ellis MJ; Ma C
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):33-43. PubMed ID: 17912634
[TBL] [Abstract][Full Text] [Related]
20. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
